Strata Skin Sciences highlights excimer laser efficacy for eczema By Investing.com
Key Takeaways
- STRATA Skin Sciences is promoting its XTRAC Excimer Laser as an effective treatment for atopic dermatitis.
- The American Medical Association expanded excimer laser indications, enabling reimbursement for atopic dermatitis treatment by Medicare, Medicaid, and private payers.
- Clinical evidence, including a 2016 study, supports the XTRAC laser's effectiveness, showing significant disease severity reduction for severe eczema.
- The company recently raised approximately $2.42 million in gross proceeds through a registered direct stock offering.
- Despite positive clinical developments and new study results for vitiligo treatment, STRATA's stock has declined by 21% over the past six months.
STRATA Skin Sciences, a medical technology company, is emphasizing the effectiveness of its XTRAC Excimer Laser for treating atopic dermatitis, coinciding with Eczema Awareness Month. A significant development is the American Medical Association's expansion of excimer laser indications to include autoimmune skin diseases, which facilitates reimbursement for atopic dermatitis treatment across major payers. Clinical data, including a 2016 study showing high rates of skin clearance for severe eczema, supports the laser's efficacy, particularly for hard-to-treat areas. Furthermore, the company recently completed a direct stock offering, raising approximately $2.42 million in gross proceeds to support its operations. STRATA is also seeing positive results from combining its 308nm Excimer laser with JAK inhibitors for vitiligo treatment and supports clinic growth through its E360 consulting program. However, despite these positive clinical and financial activities, InvestingPro analysis notes that the company's stock has faced recent downward pressure, declining 21% over the last six months.
